ArticleInternational journal of clinical and experimental medicine2015
Emodin inhibits HMGB1-induced tumor angiogenesis in human osteosarcoma by regulating SIRT1.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 26 citations in OpenAlex.
- The SIRT1-HMGB1 axis: Therapeutic potential to ameliorate inflammatory responses and tumor occurrence.Frontiers in cell and developmental biology · 2022Review
- The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers.International journal of biological sciences · 2022Review
- Anti-tumorigenic Effects of Emodin and Its' Homologue BTB14431 on Vascularized Colonic Cancer in a Rat Model.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.Chinese medicine · 2019Review
- HMGB1/RAGE axis mediates the apoptosis, invasion, autophagy, and angiogenesis of the renal cell carcinoma.OncoTargets and therapy · 2018Article
- BRAF kinase inhibitor exerts anti-tumor activity against breast cancer cells via inhibition of FGFR2.American journal of cancer research · 2016Article
- Development of Certain Protein Kinase Inhibitors with the Components from Traditional Chinese Medicine.Frontiers in pharmacology · 2016Review
- Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation.International journal of biological sciences · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledThe anti-cancer effects of emodin, including inhibition of proliferation, invasion, metastasis and angiogenesis, were confirmed by various previous studies. However, the specific mechanisms were not clear. In this study, we investigated emodin's anti-angiogenesis effect and focused on the mechanisms in human osteosarcoma (OS). OS cells were implanted to nude mice to form OS xenografts. Immunofluorescence assay was used to assess vWF expression in tumor tissue. MTT assay was employed to screen proper emodin concentrations unrelated with proliferation inhibition. siRNA technique was utilized to silence SIRT1 expression in OS cells. Expression levels of SIRT1 and VEGF were investigated by real-time PCR and western blotting. H4-k16Ac expression which indicated the deacetylation activity of SIRT1 was also detected by western blotting. As in results, HMGB1 treatment exacerbated OS angiogenesis both in vivo and in vitro. Emodin administration attenuated angiogenesis in both OS and HMGB1 treated OS in vivo and in vitro. After emodin treatment, the expression level and deacetylation activity of SIRT1 were dramatically enhanced. HMGB1-induced angiogenesis was more striking in SIRT1 silenced OS cells. SIRT1 silencing also impaired the anti-angiogenesis effect of emodin in OS cells. IN
conclusionSIRT expression and deacetylation activity elevation are involved in emodin's anti-angiogenesis effect in human OS.
Indexed as
Identifiers
26628989PMC4658878W2190587091What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.